Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/19/2022 | $3.00 → $2.75 | Buy | HC Wainwright & Co. |
| 7/27/2021 | $3.00 | Buy | Ladenburg Thalmann |
D - electroCore, Inc. (0001560258) (Filer)
10-Q - electroCore, Inc. (0001560258) (Filer)
8-K - electroCore, Inc. (0001560258) (Filer)
- SEC Filing
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, is thrilled to announce the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM™, a non-invasive vagus nerve stimulator (nVNS) designed in partnership with the US military to enhance human performance exclusively for active-duty military use. TAC-STIM is a cutting-edge device that can accelerate learning and improve mood and cognitive performance. TAC-STIM is a portable, easy-to-use tool that leverages electroCore's patented technology to deliver precise and effective vagus nerve stimulation, helping war fighters and operators learn new tasks, increase readiness and mitig
ROCKAWAY, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus, has been recognized in the inaugural Woman's World Magazine 50 over 50 Award. Products were evaluated based on quality, effectiveness, and value, with these awards honoring outstanding products for women over 50. A link to the article can be found here: Woman's World 50 Over 50 Awards. "We are thrilled to receive the Woman's World Magazine 50 over 50 Award for Truvaga Plus," stated Dan Goldberger, CEO of electroCore. "This honor highlights our dedication to creating solution
ROCKAWAY, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it has donated 20 gammaCore Sapphire D's to be used by Dr. Robin Ely, Director of Integrative and Regenerative Medicine, a global practice focused on the development of integrated treatment regimens for neurocognitive and neurodegenerative disorders, and Dr. Yori Gidron, professor of health psychology at the Dept. of Nursing, Faculty of welfare and health sciences, University of Haifa and co-author of the PTSD Clinical Practice Guideline published by the Vagus Nerve Society. The real-world evaluation will be conducted by Dr.
ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place in New York City on November 21, 2024. Joshua Lev, Chief Financial Officer, will host one-on-one meetings throughout the day. To schedule a one-on-one meeting with Mr. Lev, investors are encouraged to reach out to their CG representative. For more information regarding the event please visit https://www.meetmax.com/sched/event_110807/conference_home.html. About electroCore, Inc.electroCore, Inc. is a
ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024. "We are pleased to have been selected to join the Russell Microcap® Index," said Brian Posner, Chief Finan
FAIRFAX, Va. and TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly"), a pioneering artificial intelligence ("AI") company developing innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders, today announced the appointment of Brian M. Posner to its Board of Directors upon closing of its planned merger with WaveDancer, Inc. ("WaveDancer") (NASDAQ:WAVD). Firefly has entered into a definitive agreement and plan of merger (as amended, the "Merger Agreement") with WaveDancer, which has been approved by the stockholders of both companies and both companies are working towards meeting the final closing cond
ROCKAWAY, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Julie Bruzzone Goldstein and Tricia Wilber to the company's Board of Directors effective March 15, 2022. The Company also announced that effective March 4, 2022, Dr. Stephen Ondra is resigning from the Board to focus on his new role as Chief Medical Advisor at MITRE, and Michael Atieh will not be standing for re-election to the Board at the 2022 Annual General Meeting. "Ms. Goldstein and Ms. Wilber are successful business leaders with proven track records, and I am pleased to welcome them to our Board," said Peter Cuneo
SC 13D/A - electroCore, Inc. (0001560258) (Subject)
SC 13G/A - electroCore, Inc. (0001560258) (Subject)
SC 13D - electroCore, Inc. (0001560258) (Subject)
**Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report
HC Wainwright & Co. reiterated coverage of electroCore with a rating of Buy and set a new price target of $2.75 from $3.00 previously
Ladenburg Thalmann initiated coverage of electroCore with a rating of Buy and set a new price target of $3.00
Maxim Group resumed coverage of electroCore with a rating of Buy and set a new price target of $3.00
Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales Company to host a conference call and webcast today, November 13, 2024 at 4:30 p.m. EST ROCKAWAY, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced third quarter 2024 financial results. Recent Highlights Eighth consecutive record quarterly revenue of $6.6 million, an increase of 45% over third quarter 2023Year to date, revenue of $18.1 million; an increase of 67% over the first nine months of 2023Sales of Rx gammaCore™ and Truvaga™ before variable TAC-STIM™ sa
ROCKAWAY, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2024, after the close of the market on Wednesday, November 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions. Wednesday, November 13, 4:30 PM ESTDial-In: 877-407-8835 / +1 201-689-8779Conference ID: 13744121Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improv
LONDON, UNITED KINGDOM / ACCESSWIRE / September 4, 2024 / Ecora Resources PLC (LSE/TSX:ECOR) announces half year results for the six months ended 30 June 2024 which are available on both the Group's website at www.ecora-resources.com and on SEDAR at www.sedar.com. Ecora is the leading royalty company focused on supporting the supply of industrial commodities essential to creating a sustainable future. The Group has a portfolio which combines volume growth in 2024 and 2025 from its currently producing royalty portfolio with an extensive pipeline of high-quality development projects that are expected to drive material medium term revenue growth.Marc Bishop Lafleche, Chief Executive Officer of
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
3 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)